Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia
Open Access
- 12 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-14
- https://doi.org/10.1038/s41467-020-16720-9
Abstract
Activated protein C (APC) is a plasma serine protease with antithrombotic and cytoprotective functions. Based on the hypothesis that specific inhibition of APC’s anticoagulant but not its cytoprotective activity can be beneficial for hemophilia therapy, 2 types of inhibitory monoclonal antibodies (mAbs) are tested: A type I active-site binding mAb and a type II mAb binding to an exosite on APC (required for anticoagulant activity) as shown by X-ray crystallography. Both mAbs increase thrombin generation and promote plasma clotting. Type I blocks all APC activities, whereas type II preserves APC’s cytoprotective function. In normal monkeys, type I causes many adverse effects including animal death. In contrast, type II is well-tolerated in normal monkeys and shows both acute and prophylactic dose-dependent efficacy in hemophilic monkeys. Our data show that the type II mAb can specifically inhibit APC’s anticoagulant function without compromising its cytoprotective function and offers superior therapeutic opportunities for hemophilia.Keywords
This publication has 51 references indexed in Scilit:
- Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46Blood, 2012
- Protein C anticoagulant system—anti-inflammatory effectsSeminars in Immunopathology, 2011
- Features and development of CootActa Crystallographica Section D-Structural Biology, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D-Structural Biology, 2010
- Extracellular histones are major mediators of death in sepsisNature Medicine, 2009
- Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutantBlood, 2009
- Phasercrystallographic softwareJournal of Applied Crystallography, 2007
- Inhibitor Antibodies to Factor VIII and Factor IX: ManagementSeminars in Thrombosis and Hemostasis, 2000
- Tracking Structural Features Leading to Resistance of Activated Protein C to α1-antitrypsinBiochemistry, 2000
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D-Biological Crystallography, 1994